ABVX:EPA
Abivax SA
၈၃.၅၀ €
၀.၀၀%
(၀.၀၀) 1D
အောက် ၂, GMT+၂ ၁၇:၃၅:၂၃ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Mkt. cap
၇၂၅.၁၄ ဋေ
Avg. vol.
၁.၅၆ သိန်း
Volume
၀.၀၀
52-wk high
၁၃၉.၀၀ €
52-wk low
၆၀.၄၅ €
EPS
-၅.၂၀ €
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
Mkt. cap
၇၂၅.၁၄ ဋေ
Avg. vol.
၁.၅၆ သိန်း
Volume
၀.၀၀
52-wk high
၁၃၉.၀၀ €
52-wk low
၆၀.၄၅ €
EPS
-၅.၂၀ €
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
News stories
From web sources and news partners
Yahoo Finance
·
ပြီးခဲ့သည့် ၂၆ မိနစ်
Stock Market: Will S&P 500 Open Up or Down Today?
Briefs Finance
·
ပြီးခဲ့သည့် ၃၆ မိနစ်
OKX and ICE Launch Tokenized NYSE Stocks
TradingView
·
ပြီးခဲ့သည့် ၃၅ မိနစ်
IXIC: Nasdaq Futures Flash Green as Traders Double Down on Risk. Rate-Hike Fear Is Fading
MSN
·
ပြီးခဲ့သည့် ၁၇ နာရီ
Spiking bond yields, midterms, earnings to test US stocks' typical fourth-quarter strength
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees၉၈
Founded၂၀၁၃ ဒီ ၄
Headquarters-
Sector-
Websiteabivax.com